JP Morgan Chase
CVKD icon

JP Morgan Chase’s Cadrenal Therapeutics CVKD Stock Holding History

JP Morgan Chase’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.9K Hold
7,500
– – ﹤0.01% 6373
2025
Q4 		$50.9K Hold
7,500
– – ﹤0.01% 6222
2025
Q3 		$103K Buy
+7,500
New +$92.8K ﹤0.01% 5884
2025
Q2 		– Sell
-100
Closed -$1.76K – 7177
2025
Q1 		$1.76K Buy
+100
New +$1.84K ﹤0.01% 6562

Other funds holding CVKD

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's CVKD Position: Q1 2026 in Review

JP Morgan Chase held its Cadrenal Therapeutics (CVKD) position steady in Q1 2026 at 7,500 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6373.

JP Morgan Chase first reported a position in CVKD in Q1 2025 and has held it in 4 quarters since. The position peaked at $103K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q1 2026.

  • JP Morgan Chase held 7,500 shares of Cadrenal Therapeutics worth $31.9K as of Q1 2026.
  • JP Morgan Chase left its Cadrenal Therapeutics share count unchanged in Q1 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6373 holding.
  • JP Morgan Chase first reported a position in Cadrenal Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • JP Morgan Chase's Cadrenal Therapeutics position peaked at $103K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.